VEGF heparinized-decellularized adipose tissue scaffolds enhance tissue engineering vascularization in vitro .
Song M., Zhou Y., Liu Y.
Laboratory Study, published in RSC Adv (2018) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- RSC Adv (2018)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 35548831
- PMCID
- PMC9086570
- DOI
- 10.1039/c7ra13282d
- Citations
- 13
Abstract (original English)
Scaffolds based on decellularized adipose tissue (DAT) are gaining popularity in the adipose tissue engineering field due to their high biocompatibility and vascularizing properties. Previous studies involving decellularized adipose tissue (DAT) scaffolds have not fully demonstrated their ability to induce in vitro vascularization of engineered tissue. With the aim of developing a more effective adipose tissue engineering vascularization technique based on DAT, we investigated the vascularizing potential of a vascular endothelial growth factor (VEGF) delivery system utilizing a heparinized DAT (Hep-DAT) scaffold in vitro . To generate this system, heparins were cross-linked to DATs with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide and N -hydroxysuccinimide. Encapsulated Hep-DATs were able to control the release of a significantly higher amount of VEGF in vitro than non-heparinized DATs. Human bone marrow stromal cells (hBMSCs), when seeded on these VEGF-Hep-DATs, differentiated into endothelial cells which expressed vascular endothelial markers CD34 and VWF, thus resulting in accelerated vascularization of transplanted tissue as compared to the control DAT-only scaffold. In conclusion, these studies demonstrate that VEGF-Hep-DATs promoted greater tissue vascularization as compared to the DAT control scaffold and that VEGF-Hep-DATs are an effective and biocompatible angiogenesi
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.